Investigations Regarding B-cell Subsets in Humans
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00926692|
Recruitment Status : Completed
First Posted : June 23, 2009
Last Update Posted : August 26, 2015
|Condition or disease||Intervention/treatment|
|Healthy||Other: Blood draw|
The specific aim of this research project is to define the human equivalent of mouse B1 cells. This will be done by evaluating IgM secretion, surface markers, functional characteristics, V gene usage, N-region addition, and phosphorylation status of intracellular proteins, gene expression, sequencing of immunoglobulin genes, determination of antigenic specificity, replication history, and response to different stimuli.
The goal of this project is to begin to the translation of decades of basic science research and research in the mouse model into the human system. It is believed that properly defining this B cell subset in humans will lead to better therapeutics, prognostics and prevention for a number of disease including infections, autoimmune disease, and cancer.
|Study Type :||Observational|
|Actual Enrollment :||249 participants|
|Official Title:||Investigations Regarding B-cell Subsets in Humans|
|Study Start Date :||April 2009|
|Primary Completion Date :||July 2014|
|Study Completion Date :||July 2014|
All subjects are considered healthy
Other: Blood draw
Subject will have blood draw.
- Presence of B-1 cells in humans [ Time Frame: determined over the years study in effect ]an equivalent cell type was isolated in humans
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00926692
|United States, New York|
|Feinstein Institute for Medical Research|
|Manhasset, New York, United States, 11030|
|Principal Investigator:||Daniel Griffin, M.D.||Feinstein Institute for Medical Research|